Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A fine-tuned ensemble of tabular foundation models moderately predicted pathological complete response after TNT and showed potential to support watch-and-wait selection after recalibration.
The NO-CUT phase 2 trial shows that total neoadjuvant therapy (CAPOX-based TNT) followed by non-operative management for clinical complete responders achieved high 30‑month distant relapse‑free survival (95%) and enabled organ preservation
This international multicenter study evaluates total neoadjuvant therapy (TNT) in routine clinical practice for stage II/III rectal adenocarcinoma, demonstrating varied regimen use and confirming TNT’s efficacy across treatment strategies.
Total neoadjuvant therapy combined with watch-and-wait strategies achieves a 37% clinical complete response rate in locally advanced rectal cancer with manageable toxicity, offering an organ-preserving alternative to surgery.